1. Indications and Usage
\nUnresectable or Metastatic Nasopharyngeal Carcinoma (NPC):
\nIndicated for the treatment of adult and pediatric patients (\u22656 years) with recurrent or metastatic NPC who have progressed after platinum-based chemotherapy, or as first-line treatment in combination with cisplatin and gemcitabine.
\nUnresectable or Metastatic Melanoma:
\nIndicated for the treatment of adult patients with unresectable or metastatic melanoma who have progressed after prior therapy.
\nLocally Advanced or Metastatic Urothelial Carcinoma:
\nIndicated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma who have progressed during or following platinum-containing chemotherapy.
\nRecurrent or Metastatic Cervical Cancer:
\nIndicated in combination with chemotherapy for persistent, recurrent, or metastatic cervical cancer.
\n2. Dosage and Administration
\nRecommended Dosage:
\nFixed Dose: 240 mg administered intravenously every 3 weeks.
\nWeight-based Dose (Specific Indications): 3 mg\/kg administered intravenously every 2 weeks (e.g., for melanoma or urothelial carcinoma in certain regions).
\nAdministration:
\nAdminister as an intravenous infusion over 30 to 60 minutes. Do not administer as an intravenous push or bolus.
\n3. Mechanism of Action
\nPD-1 Blockade:
\nToripalimab binds to the PD-1 receptor on T-cell surfaces and blocks its interaction with ligands PD-L1 and PD-L2.
\nImmunological Effect:
\nThis blockade prevents the inhibition of T-cell proliferation and cytokine production, thereby enhancing anti-tumor immune responses and inhibiting tumor growth.
\n4. Safety and Warnings
\nImmune-Mediated Adverse Reactions:
\nToripalimab can cause severe or fatal immune-mediated adverse reactions (e.g., pneumonitis, colitis, hepatitis, endocrinopathies). Monitor patients closely.
\nInfusion-Related Reactions:
\nInfusion-related reactions may occur. Monitor during infusion and interrupt or discontinue if severe.
\nEmbryo-Fetal Toxicity:
\nMay cause fetal harm. Advise females of reproductive potential to use effective contraception during treatment and for at least 2 months after the final dose.
\n5. Adverse Reactions
\nMost Common:
\nFatigue, diarrhea, pyrexia, rash, pruritus, decreased appetite, cough, nausea, and increased transaminases.
\n6. Drug Interactions
\nImmunosuppressants:
\nAvoid systemic corticosteroids or other immunosuppressants prior to starting treatment as they may interfere with pharmacodynamic activity.
\nMetabolic Enzymes:
\nToripalimab is not metabolized by CYP450 enzymes; therefore, drug interactions via metabolic pathways are not expected.
\n7. Pharmaceutical Information
\nChemical Composition:
\nActive Ingredient: Toripalimab.
\nStorage:
\nStore at 2\u00b0C to 8\u00b0C (36\u00b0F to 46\u00b0F). Protect from light.<\/p>\n","protected":false},"excerpt":{"rendered":"
Brand Name: \u62d3\u76ca \u00ae(Tuoyi\u00ae)
\nGeneric Name: Toripalimab
\nStrength: 240mg (6mL) per vial, 1 vial per box
\nManufacturer: Suzhou Zhonghe Biomedicine Technology Co., Ltd.
\nMarketing Authorization Holder: Shanghai Junshi Biosciences Co., Ltd.
\nApproval Date in China: December 17, 2018
\nRegistration Number: \u56fd\u836f\u51c6\u5b57 S20180015
\nStorage: Store and transport at 2\u2103 ~ 8\u2103, protect from light, do not freeze, keep out of reach of children<\/p>\n
Price&Cost:Contact Us now for the best price of Toripalimab(Tuoyi)<\/p>\n","protected":false},"featured_media":3329,"comment_status":"open","ping_status":"closed","template":"","meta":[],"product_brand":[],"product_cat":[25,73],"product_tag":[],"class_list":["post-3328","product","type-product","status-publish","has-post-thumbnail","product_cat-injection","product_cat-chinese-innovative-drug","first","instock","shipping-taxable","product-type-simple"],"yoast_head":"\n